NovaBay Pharmaceuticals, Inc. http://novabaypharma.com, a biopharmaceutical company developing products for the treatment or prevention of a wide range of bacterial and viral infections, rang the opening bell at the American Stock Exchange on Friday, January 25, 2008.
NovaBay completed its Initial Public Offering in October and commenced trading on October 26, 2007.
I was honored to ring the American Stock Exchange bell on behalf of NovaBay Pharmaceuticals,” commented Ron Najafi, CEO of NovaBay. “Having completed our IPO in October, we are delighted to join the ranks of publicly traded companies listed on the AMEX. We believe this will be an exciting year for NovaBay as we continue to focus on developing innovative product candidates targeting the treatment and prevention of bacterial, fungal and viral infections to meet the increasing need in hospital and non-hospital environments.”
To view the video of NovaBay’s bell-ringing ceremony, please visit the AMEX at: http://www.amex.com/atamex/news/events/2008/br_NBY_012508.html
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative product candidates for the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of non-antibiotic anti-infective compounds, which it has named Aganocide® compounds, based upon small molecules generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide® compounds could form a platform on which to create a variety of products to address different needs in the prevention and treatment of bacterial, fungal and viral infections, including MRSA. NovaBay has entered into a licensing and research collaboration agreement with an affiliate of Alcon, Inc. for use of the Aganocide® compounds in eye, ear and sinus infections and in contact lens solutions. NovaBay has also entered into a license agreement with an affiliate of Kinetic Concepts, Inc. for the use of NovaBay’s NeutroPhase product in wound care applications.
NovaBay(TM), AgaNase(TM), Aganocide® and NeutroPhase(TM) are trademarks of NovaBay Pharmaceuticals, Inc. All other trademarks and trade names are the property of their respective owners.
For more information visit the company’s website at: www.novabaypharma.com
This release contains forward-looking statements, which are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the development and potential benefits of, and the market opportunities for, NovaBay’s product candidates. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in discovery, development, testing, regulatory approval, production and marketing of the company’s product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company’s intellectual property or trade secrets, the company’s ability to obtain additional financing as necessary and unanticipated research and development and other costs. The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
The Investor Relations Group
Adam Holdsworth / Rachel Colgate / Erica Ruderman
Janet Vasquez / Laura Colontrelle